In parallel, the Notch pathway became an attractive therapeutic target and several tools (e.g., γ-secretase inhibitors, neutralizing antibodies against DLL4 or Notch1) that interfere with Notch signaling are currently being developed and tested in various murine cancer models or even in clinical trials [41–43]. This evidence concerns the gene DLL4 and cancer.